About Cytochroma Inc.:

Cytochroma Inc. is a development stage specialty pharmaceutical company focused on the treatment and prevention of disorders related to Vitamin D insufficiency. The Company has a portfolio of therapeutics with lower development risk for the indications of Vitamin D insufficiency and for secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). Cytochroma’s pipeline products address significant unmet medical needs with a target market that is expected to grow significantly, reaching more than $1.2 billion annually by 2010 in North America alone.

Cytochroma’s understanding of the biology of Vitamin D combined with our management’s experience in the development and commercialization of Vitamin D therapies, uniquely positions us to positively impact the outcomes of CKD patients suffering from diseases related to Vitamin D insufficiency.